Phase I study of weekly nab‐paclitaxel combined with S‐1 in patients with human epidermal growth factor receptor type 2‐negative metastatic breast cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|6|734-739

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.6, 2015-06, pp. : 734-739

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epidermal growth factor receptor and AKT1 gene copy numbers by multi‐gene fluorescence in situ hybridization impact on prognosis in breast cancer

By  

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 642-649

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association between serum ligands and the skin toxicity of anti‐epidermal growth factor receptor antibody in metastatic colorectal cancer

By  

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 604-610

John Wiley & Sons Inc

Access to resources Recommend Favorite

DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancer

By  

Cancer Science, Vol. 106, Iss. 12, 2015-12 ,pp. : 1722-1729

John Wiley & Sons Inc

Access to resources Recommend Favorite

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

By  

Cancer Science, Vol. 107, Iss. 9, 2016-09 ,pp. : 1179-1186

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I pilot study of Wilms tumor gene 1 peptide‐pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer

By  

Cancer Science, Vol. 106, Iss. 4, 2015-04 ,pp. : 397-406

John Wiley & Sons Inc

Access to resources Recommend Favorite